On Tuesday, Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial.

The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients.

DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart.

Also Read: Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure.

The trial enrolled 41 patients who received either low-dose ifetroban (150 mg per day), high-dose ifetroban (300 mg per day), or placebo.

The study’s primary endpoint was an improvement in the heart’s left ventricular ejection fractions (LVEF), a key indicator of how well the heart is pumping blood. 

Key findings include:

• High-dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.
• The high-dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%
• The difference was even more pronounced when compared with propensity-matched natural history controls, with the high-dose treatment providing a significant 5.4% overall improvement in LVEF, while the control patients experienced a 3.6% decline.
• Both doses of ifetroban were well-tolerated, with no serious drug-related events.

Ifetroban has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.

Price Action: CPIX stock is up 23.01% at $2.62 at the last check Tuesday.

Read Next:

• Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.